Selective Liver Estrogen Receptor α Modulation Prevents Steatosis, Diabetes, and Obesity Through the Anorectic Growth Differentiation Factor 15 Hepatokine in Mice.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
15
02
2019
accepted:
28
03
2019
entrez:
16
7
2019
pubmed:
16
7
2019
medline:
16
7
2019
Statut:
epublish
Résumé
Hepatocyte estrogen receptor α (ERα) was recently recognized as a relevant molecular target for nonalcoholic fatty liver disease (NAFLD) prevention. The present study defined to what extent hepatocyte ERα could be involved in preserving metabolic homeostasis in response to a full (17β-estradiol [E2]) or selective (selective estrogen receptor modulator [SERM]) activation. Ovariectomized mice harboring a hepatocyte-specific
Identifiants
pubmed: 31304450
doi: 10.1002/hep4.1363
pii: HEP41363
pmc: PMC6601326
doi:
Types de publication
Journal Article
Langues
eng
Pagination
908-924Références
J Nutr. 2001 Sep;131(9):2351-7
pubmed: 11533278
Nat Rev Drug Discov. 2003 Mar;2(3):205-13
pubmed: 12612646
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Endocr Rev. 2004 Feb;25(1):45-71
pubmed: 14769827
BMJ. 2005 Apr 23;330(7497):932
pubmed: 15746106
FASEB J. 2005 Jul;19(9):1108-19
pubmed: 15985534
Diabetes. 2006 May;55(5):1327-36
pubmed: 16644689
Nat Med. 2007 Nov;13(11):1333-40
pubmed: 17982462
Cell Metab. 2008 Dec;8(6):468-81
pubmed: 19041763
Endocrinology. 2009 Apr;150(4):1688-96
pubmed: 19074584
J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):233-40
pubmed: 19429427
J Neurosci. 2009 Oct 28;29(43):13640-8
pubmed: 19864576
Hepatology. 2010 Oct;52(4):1258-65
pubmed: 20658461
Nature. 2011 Feb 10;470(7333):279-83
pubmed: 21160473
EMBO J. 1990 Sep;9(9):2811-8
pubmed: 2118104
Cell Metab. 2011 Feb 2;13(2):205-14
pubmed: 21284987
Cell Metab. 2011 Oct 5;14(4):453-65
pubmed: 21982706
PLoS One. 2012;7(4):e34868
pubmed: 22514681
Diabetes. 2013 Feb;62(2):424-34
pubmed: 22966069
J Toxicol Sci. 2012;37(5):931-42
pubmed: 23038002
Nat Med. 2012 Dec;18(12):1847-56
pubmed: 23142820
PLoS One. 2013;8(2):e57458
pubmed: 23451233
Endocr Rev. 2013 Jun;34(3):309-38
pubmed: 23460719
PLoS One. 2013;8(2):e55174
pubmed: 23468844
Physiol Behav. 2013 Jul 2;119:17-24
pubmed: 23688948
Diabetes. 2013 Dec;62(12):4098-108
pubmed: 23903353
Mol Metab. 2014 Jan 09;3(2):177-90
pubmed: 24634829
PLoS One. 2014 Jun 27;9(6):e100370
pubmed: 24971956
J Hepatol. 2015 Jul;63(1):183-90
pubmed: 25720568
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:306-21
pubmed: 26033249
Mol Endocrinol. 2016 Jul;30(7):709-32
pubmed: 27164166
Am J Pathol. 2017 Jun;187(6):1273-1287
pubmed: 28502695
Nat Med. 2017 Oct;23(10):1150-1157
pubmed: 28846097
Nat Med. 2017 Oct;23(10):1215-1219
pubmed: 28846098
Nat Med. 2017 Oct;23(10):1158-1166
pubmed: 28846099
Sci Rep. 2018 May 1;8(1):6789
pubmed: 29717162
Pharmacol Ther. 2018 Sep;189:123-129
pubmed: 29730442
Mol Ther Nucleic Acids. 2018 Sep 7;12:309-318
pubmed: 30195769
Nature. 2018 Oct;562(7727):367-372
pubmed: 30283141
Endocrinology. 2019 Apr 1;160(4):782-790
pubmed: 30759201
J Biol Chem. 1994 Apr 15;269(15):11572-7
pubmed: 8157689
Am J Physiol. 1993 Jun;264(6 Pt 2):R1219-23
pubmed: 8322977
Bone. 1997 Jan;20(1):31-9
pubmed: 8988345
Circulation. 1997 Mar 18;95(6):1542-8
pubmed: 9118523